Save the Date: In November, Intellia will present updated data from the ongoing Phase 1 study of NTLA-2001 for the potential treatment of #ATTR and hold an investor call to share third quarter 2023 earnings. Full details here: bit.ly/3QynQDI #CRISPR #GeneEditing

Heartfelt congratulations to the $VRTX and $CRSP teams!!!

Congratulations to ⁦Vertex Pharmaceuticals⁩ and ⁦CRISPR Therapeutics⁩ on FDA’s approval of @Casgevy (exa-cell), and to all who contributed to this momentous approval! fda.gov/news-events/pr…

Huge congratulations to Vertex Pharmaceuticals and CRISPR Therapeutics for making history with the first-ever FDA approval of a #CRISPR therapy!

Two for two! Congrats to the team on our second NEJM publication demonstrating the promise of #CRISPR!

$NTLA News: This morning, Intellia announced a strategic collaboration with ReCode Therapeutics to develop novel #geneeditingtherapies for #cysticfibrosis. Full details here: ir.intelliatx.com/news-releases/… #CRISPR #CF

Delivery, delivery, delivery! Join us in Siracusa, Italy from April 4-7 to discuss new advances in nucleic acid delivery and how to solve the remaining challenges! Don't miss this opportunity. Abstract deadline is March 15, 2024. Register here: engconf.us/conferences/bi…

Significant milestone achieved! Our first patient has been dosed in the MAGNITUDE study for #ATTR. Congrats to the team! #CRISPR #GeneEditing

Heartfelt congratulations to Professor José M. Polo on being elected as Fellow of the Australian Academy of Sciences!!! science.org.au/news-and-event… Learn more about José's research here: researchers.adelaide.edu.au/profile/jose.p… I’m so proud of you!!! #proudaunt

What a great time to be at Intellia! More good news from our NTLA-2002 program for #hereditaryangioedema. Congrats to the team! #CRISPR #OneIntellia

Thank you Brad Loncar for the opportunity to talk about how $NTLA is advancing the field of #geneediting medicines!

Round of applause to the $NTLA team today! Great news from our #AATDProgram Congratulations! #CRISPR #GeneEditing

#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the ACAAI Scientific Meeting in Boston. Details here: ir.intelliatx.com/news-releases/…

This encouraging data update brings us one step closer to making CRISPR-based medicines a reality through innovative science. Excited for the future as we continue to move forward! #HAE #CRISPR #OneIntellia

Impressive data update from our nex-z program (aka NTLA-2001 for #ATTR)! Congrats to all! Teamwork makes the dream work. #OneIntellia

nex z NEJM article: nejm.org/doi/full/10.10…

Wishing you a year filled with positivity, creativity, and a commitment to making the world a better place. Let's embrace each day with a spirit of discovery and a drive to create beauty around us. Here's to a year of growth, kindness, and meaningful contributions. #NewYear2025

We made the tough call to restructure our business operations, affecting many of our skilled colleagues. I am committed to supporting them through this transition and serving as a personal reference where I can. Your consideration is greatly appreciated. #ONEintellia #talent

I am honored to join the Board of AskBio Inc. (AskBio) Inc. during such a pivotal moment as it advances its clinical and pre-clinical programs toward major milestones. Eager to help realize the full potential of these groundbreaking medicines! #CGT #genetherapy #AAV #BOD